ANDA 40615, held by Caplin One Labs. Testosterone Cypionate.
As of Nov 16, 2026, ANDA 40615 (Testosterone Cypionate), held by Caplin One Labs, was first approved by FDA on Aug 10, 2006, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 10, 2006 | Original application | Approved | None posted |
| Testosterone Cypionate100MG/ML · injectable;injection | Testosterone Cypionate | Discontinued |
| Testosterone Cypionate200MG/ML · injectable;injection | Testosterone Cypionate | Discontinued |
| Jul 11, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| Oct 25, 2016 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 11, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jun 19, 2014 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 10, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters